Exeliom Biosciences Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$26M
- Investors
-
12
Exeliom Biosciences General Information
Description
Developer of immunotherapies designed to help harness the therapeutic potential of gut microbiota. The company develops single bacterial strain drug candidates to deliver microbiome-based immunotherapy for treating inflammatory bowel diseases and cancer, starting with Crohn's Disease as a first indication, enabling patients to lead longer and healthier lives by accessing their medicines derived from microbiota.
Contact Information
Website
www.exeliombio.comCorporate Office
- 67 Rue Des Godrans
- 21000 Dijon
- France
Corporate Office
- 67 Rue Des Godrans
- 21000 Dijon
- France
Exeliom Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series A) | 30-Jun-2023 | $26M | 0000 | Completed | Clinical Trials - Phase 1 | |
| 3. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 2. Grant | 03-Aug-2020 | $2.87M | Completed | Clinical Trials - Phase 1 | ||
| 1. Grant | 12-Aug-2019 | $2.01M | Completed | Clinical Trials - Phase 1 |
Exeliom Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Exeliom Biosciences Patents
Exeliom Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4389134-A1 | Faecalibacterium prausnitzii strain cncm i-4573 for the treatment and prevention of clostridioides difficile infection | Pending | 20-Dec-2022 | 0000000000 | 0 |
| EP-4166150-A1 | Association of a faecalibacterium prausnitzii strain and anti-pd-1, anti-pd-l1 or anti-ctla-4 antibodies for the treatment of cancer | Pending | 15-Oct-2021 | 0000000000 | 0 |
| CA-3235021-A1 | Association of a faecalibacterium prausnitzii strain and anti-pd-1, anti-pd-l1 or anti-ctla-4 antibodies for the treatment of cancer | Pending | 15-Oct-2021 | 0000000000 | |
| AU-2022366208-A1 | Association of a faecalibacterium prausnitzii strain and anti-pd-1, anti-pd-l1 or anti-ctla-4 antibodies for the treatment of cancer | Pending | 15-Oct-2021 | 0000000000 | |
| EP-4415734-A1 | Association of a faecalibacterium prausnitzii strain and anti-pd-1, anti-pd-l1 or anti-ctla-4 antibodies for the treatment of cancer | Pending | 15-Oct-2021 | A61K35/741 |
Exeliom Biosciences Executive Team (4)
| Name | Title | Board Seat |
|---|---|---|
| Benjamin Hadida | Co-Founder, Chief Executive Officer, President & Board Member | |
| Philippe Langella Ph.D | Co-Founder & Advisor | |
| Patrick Gervais | Co-Founder | |
| Harry Sokol Ph.D | Co-Founder, Chief Medical Officer ad interim, Advisor & Board Member |
Exeliom Biosciences Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Benjamin Hadida | Exeliom Biosciences | Co-Founder, Chief Executive Officer, President & Board Member | 000 0000 |
| David Sourdive Ph.D | Elaia Partners | Board Member | 000 0000 |
| Franck Lescure | Self | Board Member | 000 0000 |
| François Miceli | UI Investissement | Board Member | 000 0000 |
| Harry Sokol Ph.D | Exeliom Biosciences | Co-Founder, Chief Medical Officer ad interim, Advisor & Board Member | 000 0000 |
Exeliom Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Exeliom Biosciences Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Auriga Partners (Paris) | Venture Capital | Minority | 000 0000 | 000000 0 |
| Biocodex | Corporation | Minority | 000 0000 | 000000 0 |
| Capital Grand Est | PE/Buyout | Minority | 000 0000 | 000000 0 |
| CE-Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |
| Elaia Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Exeliom Biosciences FAQs
-
When was Exeliom Biosciences founded?
Exeliom Biosciences was founded in 2016.
-
Who is the founder of Exeliom Biosciences?
Benjamin Hadida, Philippe Langella Ph.D, Patrick Gervais, and Harry Sokol Ph.D are the founders of Exeliom Biosciences.
-
Who is the CEO of Exeliom Biosciences?
Benjamin Hadida is the CEO of Exeliom Biosciences.
-
Where is Exeliom Biosciences headquartered?
Exeliom Biosciences is headquartered in Dijon, France.
-
What is the size of Exeliom Biosciences?
Exeliom Biosciences has 8 total employees.
-
What industry is Exeliom Biosciences in?
Exeliom Biosciences’s primary industry is Drug Discovery.
-
Is Exeliom Biosciences a private or public company?
Exeliom Biosciences is a Private company.
-
What is Exeliom Biosciences’s current revenue?
The current revenue for Exeliom Biosciences is 000000.
-
How much funding has Exeliom Biosciences raised over time?
Exeliom Biosciences has raised $26M.
-
Who are Exeliom Biosciences’s investors?
Auriga Partners (Paris), Biocodex, Capital Grand Est, CE-Ventures, and Elaia Partners are 5 of 12 investors who have invested in Exeliom Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
